Reuters reported Bank of America Merrill Lynch and Mizuho Bank are leading the financing for a $7 billion financing package supporting generic drugmaker Actavis’ acquisition of Forest Laboratories, in the first sizeable bridge loan to be syndicated in the U.S. this year.

According to em> Reuters , Dublin-based Actavis, the world’s third-largest generics prescription drug manufacturer, recently announced plans to buy Forest Laboratories with cash and equity valued at approximately $25 billion, or $89.48 per Forest share.

To read the entire Reuters article, click here.